RecruitingPhase 2NCT04655118

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Studying Indolent systemic mastocytosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Telios Pharma, Inc.
Intervention: TL-895(drug)
Enrollment: 121 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2025

Study locations (30)

University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Gabrail Cancer Center, Canton, Ohio, United States
University of Cincinnati (UC) Physicians Company, LLC, Cincinnati, Ohio, United States
Ohio State University, Columbus, Ohio, United States
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Border Medical Oncology, East Albury, Australia
Southern Oncology Specialists, Kogarah, Australia
Royal Perth Hospital, Perth, Australia
St Vincent's Hospital Sydney, Sydney, Australia
Chu De Liège, Liège, Belgium
Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas, São Paulo, Brazil
University Hospital "St Ivan Rilski", Sofia, Bulgaria
Military Medical Academy, Sofia, Bulgaria
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04655118 on ClinicalTrials.gov

Other trials for Indolent systemic mastocytosis

Additional recruiting or active studies for the same condition.

See all trials for Indolent systemic mastocytosis →

← Back to all trials